Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation
- PMID: 11588308
- DOI: 10.1161/hs1001.097090
Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation
Abstract
Background and purpose: We sought to assess in outpatients with atrial fibrillation and oral anticoagulation (1) whether the complication rate is influenced by the presence of the risk factors age >65 years, arterial hypertension, diabetes, or previous stroke; (2) whether the complication rate is influenced by the number of additional drugs taken by patients; and (3) whether problems and interventions differ between patients with or without complications.
Methods: - Clinical characteristics, drugs, problems, interventions, and complications were registered during 2 years.
Results: - Three hundred sixty patients (mean age, 68 years; 43% female) were observed for 383 patient-years. Patients aged >65 years had more serious, life-threatening, or fatal complications (11% versus 5.3%/100 patient-years; P=0.0428) than younger patients. Patients with diabetes had more life-threatening and fatal complications (2.8% versus 0.6%/100 patient-years; P=0.0354) than patients without. The complication rate did not differ regarding the presence of previous stroke or hypertension. Patients who took </=3 drugs had fewer complications than patients who took more (4.3% versus 24.4%/100 patient-years; P=0.0041). Patients with complications complained more of chest (48% versus 28%/100 patient-years; P=0.0113) and abdominal pain (30% versus 13%/100 patient-years; P=0.0057), more frequently failed to keep appointments (134% versus 107%/100 patient-years; P=0.0321), had a higher tracking rate (134% versus 105%/100 patient-years; P=0.0272), and took more additional drugs (4.6 versus 3.5 drugs per day; P=0.0063) than patients with no complications.
Conclusions: - Patients with increased age or diabetes mellitus or those who take >3 drugs per day have an increased complication rate and thus need especially careful monitoring of oral anticoagulation, including adequate pain control.
Comment in
-
Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation.Stroke. 2002 Sep;33(9):2150-2; author reply 2150-2. doi: 10.1161/01.str.0000028777.28420.e8. Stroke. 2002. PMID: 12215576 No abstract available.
Similar articles
-
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3. Circulation. 2014. PMID: 24895454 Clinical Trial.
-
Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.J Cardiovasc Electrophysiol. 2016 Feb;27(2):147-53. doi: 10.1111/jce.12856. Epub 2015 Nov 23. J Cardiovasc Electrophysiol. 2016. PMID: 26464027
-
Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation.Am J Med. 2011 Feb;124(2):111-4. doi: 10.1016/j.amjmed.2010.05.007. Epub 2010 Sep 29. Am J Med. 2011. PMID: 20887966
-
Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.Prog Cardiovasc Dis. 2015 Sep-Oct;58(2):177-94. doi: 10.1016/j.pcad.2015.07.003. Epub 2015 Jul 7. Prog Cardiovasc Dis. 2015. PMID: 26162958 Review.
-
Primary and secondary stroke prevention in nonrheumatic atrial fibrillation by oral anticoagulation.Eur Neurol. 2003;50(3):127-35. doi: 10.1159/000073052. Eur Neurol. 2003. PMID: 14530617 Review.
Cited by
-
Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study.Clin Cardiol. 2004 Jan;27(1):40-6. doi: 10.1002/clc.4960270111. Clin Cardiol. 2004. PMID: 14743856 Free PMC article.
-
Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors.Egypt Heart J. 2018 Mar;70(1):45-49. doi: 10.1016/j.ehj.2018.01.001. Epub 2018 Feb 1. Egypt Heart J. 2018. PMID: 29622997 Free PMC article.
-
Approaches to prevention of cardiovascular complications and events in diabetes mellitus.Drugs. 2007;67(7):997-1026. doi: 10.2165/00003495-200767070-00005. Drugs. 2007. PMID: 17488145 Review.
-
Left atrial appendage occlusion: A better alternative to anticoagulation?World J Cardiol. 2017 Feb 26;9(2):139-146. doi: 10.4330/wjc.v9.i2.139. World J Cardiol. 2017. PMID: 28289527 Free PMC article. Review.
-
The safety and adequacy of antithrombotic therapy for atrial fibrillation: a regional cohort study.Br J Gen Pract. 2006 Sep;56(530):697-702. Br J Gen Pract. 2006. PMID: 16954003 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical